Artivion (NYSE:AORT) Stock Price Target Cut by Citizens Jmp

Artivion (NYSE:AORT) had its price target decreased by equities researchers at Citizens Jmp from $48.00 to $42.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp‘s target price suggests a potential upside of 96.05% from the company’s previous close.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group set a $30.00 price objective on Artivion in a report on Friday. Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings cut shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Needham & Company LLC reiterated a “buy” rating and set a $44.00 price target on shares of Artivion in a research report on Monday, July 20th. Finally, Citigroup reissued a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.57.

Artivion Trading Down 15.4%

Shares of AORT traded down $3.91 during trading hours on Friday, hitting $21.42. 238,201 shares of the stock traded hands, compared to its average volume of 596,020. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. Artivion has a 1-year low of $19.16 and a 1-year high of $48.25. The firm has a market capitalization of $1.04 billion, a PE ratio of -307.81 and a beta of 1.31. The business has a fifty day moving average of $23.67 and a 200-day moving average of $29.09.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.14. The business had revenue of $123.79 million for the quarter, compared to analysts’ expectations of $120.97 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Analysts expect that Artivion will post 0.45 EPS for the current year.

Insider Transactions at Artivion

In related news, SVP Andrew M. Green sold 11,480 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $24.97, for a total value of $286,655.60. Following the completion of the sale, the senior vice president owned 40,160 shares in the company, valued at approximately $1,002,795.20. This represents a 22.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO James P. Mackin sold 70,000 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the transaction, the chief executive officer directly owned 877,275 shares in the company, valued at $25,397,111.25. The trade was a 7.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 90,460 shares of company stock worth $2,557,366 in the last three months. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Artivion

Institutional investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. increased its stake in shares of Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after acquiring an additional 399 shares during the last quarter. Pinnacle Wealth Planning Services Inc. raised its position in shares of Artivion by 362.8% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,379 shares of the company’s stock valued at $31,000 after acquiring an additional 1,081 shares during the period. Versant Capital Management Inc boosted its stake in Artivion by 38.0% during the 3rd quarter. Versant Capital Management Inc now owns 2,119 shares of the company’s stock worth $48,000 after acquiring an additional 584 shares during the last quarter. Fulcrum Asset Management LLP bought a new position in Artivion during the 3rd quarter worth approximately $49,000. Finally, Quantbot Technologies LP bought a new position in Artivion during the 2nd quarter worth approximately $103,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analyst estimates of about $121 million. Artivion also projected 2026 revenue of $484 million to $492 million, signaling continued growth. Artivion Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company is preparing to launch its NEXUS aortic product in January 2027, a potential growth catalyst as it expands its product portfolio. Artivion outlines 2026 revenue and NEXUS launch
• Negative Sentiment: Profitability was weaker: Artivion reported a GAAP net loss of $7.9 million, while adjusted EPS of $0.08 fell short of Zacks’ $0.11 consensus and compared with $0.16 a year earlier. Adjusted EBITDA declined 8% to $22.5 million, which may temper the positive revenue news. Artivion lags Q3 earnings estimates
• Negative Sentiment: Canaccord lowered its price target on AORT to $30, a sign of reduced analyst expectations that could add pressure despite the company’s revenue growth. Canaccord lowers Artivion price target

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.